ClinicalTrials.gg
Not yet recruitingNCT06883188STOPUpdated Oct 26, 2026

Stop Air Leak by Talc or Autologous Blood Patch Therapy

A Phase 2/3 interventional study of talc powder and patient's own venous blood in Pneumothorax Spontaneous Secondary, sponsored by Chinese University of Hong Kong. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Chinese University of Hong Kong · Phase 2/3, Interventional, and Treatment

How we know

Updated Oct 26, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background: A pilot study to assess the feasibility of a randomisation trial protocol comparing intrapleural talc pleurodesis versus autologous blood patch therapy (ABPT) in patients with secondary spontaneous pneumothorax (SSP) complicated by persistent air leak (PAL). The investigators hypothesise that the proposed protocol will be feasible.

Methods: A multicentre, two-arm, open-label, randomised controlled feasibility study which includes non-surgical subjects with SSP and PAL persisting for 3 days. Recruited subjects will be randomised in a 1:1 ratio to receive one dose of talc pleurodesis or ABPT, with follow-ups up to 3 months after hospital discharge.

Discussion: The main outcome is to assess the feasibility of the trial protocol, based on the percentage of eligible patients enrolled and randomised, retained to discharge, and completing 3 months of follow-up. Other important outcomes include complete cessation of air leak and successful chest drain removal within 72 hours after the study intervention, absolute and percentage changes in digitally measured air leak rates, duration of chest drainage, recurrence of ipsilateral pneumothorax, need for additional pleural interventions, safety outcomes such as drain blockage and pleural infection. Feasibility outcomes will be reported as descriptive data. Comparison of outcomes between the two treatment groups will be analysed on an intention-to-treat basis. Safety outcomes will be reported descriptively for each group. The reported estimates of recruitment rates, adherence, follow-up completeness, and variability and event rates for key clinical outcomes will be used to inform sample size calculations for future studies incorporating the current study design.

Read the detailed description

Pneumothorax, defined as the presence of air in the pleural space, is a common respiratory emergency that often necessitates prolonged hospitalisation. In cases where pneumothorax occurs in the setting of underlying chronic lung diseases (secondary spontaneous pneumothorax, SSP), the clinical course is considerably more severe. SSP patients are typically more hypoxic, more likely to develop persistent air leak (PAL), and experience longer hospital stays with higher in-patient mortality compared to those with primary spontaneous pneumothorax (PSP).

The management of SSP with PAL remains controversial despite its clinical significance. Numerous strategies, including chemical pleurodesis, autologous blood patch therapy (ABPT), implantation of endobronchial valves (EBV), and surgical pleurodesis, are employed in practice. However, many SSP patients are unsuitable for invasive procedures such as EBV placement or surgery, owing to their poor premorbid status. In this context, ABPT and chemical pleurodesis (often using talc) emerge as low-cost, bedside alternatives. Yet, current practices vary widely, and a lack of robust comparative evidence has left clinicians with no definitive guidance regarding the optimal management approach.

Talc pleurodesis, involving the intrapleural instillation of sterile talc powder, is a commonly adopted treatment for SSP with PAL in Hong Kong. Retrospective studies indicate that 37% to 45% of SSP patients undergo chemical pleurodesis, with talc being the predominant agent. Reported treatment success is around 70%, with a median drainage duration of 12 days post-procedure. Adverse events, most notably chest pain affecting roughly one-third of patients, are not uncommon, although more serious complications such as respiratory distress occur in only 1.6% of cases. Nonetheless, these findings are derived from studies with retrospective designs and variable methodologies, limiting firm conclusions on efficacy and safety.

In contrast, ABPT has been proposed as a promising alternative for managing PAL. This technique involves the intrapleural instillation of autologous blood with the aim of sealing the air leak, initially developed for PAL in post-operative pneumothorax. Several small-scale retrospective and prospective studies have suggested that ABPT can achieve cessation in 26% to 91% of cases, with some reports showing 72% to 84% of patients experiencing complete resolution within five days. Moreover, ABPT appears safe for repeated administration, with adverse events reported at incidences ranging from 0% to 16%. However, the heterogeneous outcomes likely reflect differences in blood dosage, timing of intervention, number of administrations, and varying definitions of PAL among studies.

Given the controversy and the limitations of existing evidence, a multicentre randomised controlled trial (RCT) comparing talc pleurodesis with ABPT is imperative. To achieve this, a pilot study is designed to rigorously address methodological weaknesses by standardising the timing of pleural interventions, employing a digital chest drain system for precise, quantitative measurement of air leak, and adopting unified criteria for treatment success.

02

Conditions studied

  • Pneumothorax Spontaneous Secondary

Browse trials for

Keywords

  • Persistent air leak
  • talc pleurodesis
  • autologous blood patch therapy
03

In context

Pneumothorax

183 studies on the registry are indexed under Pneumothorax; 41 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 111 interventional studies indexed under Pneumothorax.

Browse Pneumothorax studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Radiographically proven pneumothorax and underlying lung disease (either pre-existing or shown in diagnostic imaging at presentation)
  • Spontaneous onset of pneumothorax, not related to trauma or iatrogenic procedure
  • SSP with air leak persists for at least 2 days after the first radiographic evidence of pneumothorax
  • Not suitable, as decided by the attending medical or surgical team, or the patient is unwilling to receive surgical management for the pneumothorax

Exclusion criteria

Exclusion Criteria:

  • Inability to give
  • A chest drain size smaller than Fr 12
  • Bilateral pneumothorax.
  • Impaired blood clotting, including baseline > 1.5, \< 150 x 109/L, or use of therapeutic dose anticoagulant or dual-antiplatelet agents.
  • Active or recent (within 6 weeks) ipsilateral pleural infection.
  • Septicemia or active extra-pleural infection (e.g. pneumonia).
  • Use of long-term systemic or .
  • Previously received talc or ABPT to the ipsilateral pleural space for the current episode of pneumothorax.
  • Known sensitivity to talc.
  • Has had a previous pneumonectomy (either on the same or contralateral side).
  • Patients who are pregnant or lactating (females of must have a negative pregnancy test before randomisation).
  • Expected survival of less than three months from a different pathology to the current episode of pneumothorax (e.g. ).
  • Cognitively impaired patients who are at risk of self-removing the chest drain
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    talc pleurodesis

    intrapleural instillation of talc slurry

    Drug: talc powder

  • Active comparator
    Autolougs blood patch therapy (ABPT)

    intrapleural instillation of patient's venous blood

    Biological: patient's own venous blood

Interventions

  • Drugtalc powder

    intrapleural instillation of talc slurry

  • Biologicalpatient's own venous blood

    intrapleural instillation of patient's own venous blood

06

What researchers measure

Primary outcomes

  1. Feasibility of pilot study trial protocol including the following criteria

    Study feasibility based on recruitment rate (number of eligible patients enrolled and successfully randomised), adherence rate (to the allocated study intervention) and retention rate (completed 3 months of follow-up)

    Time frame: 3 months

Secondary outcomes

  1. Complete cessation of air leak

    Complete cessation of air leak for more than 24 hours and successful chest drain removal

    Time frame: 72 hours

  2. Change in air leak

    Absolute reduction and percentage change in the average rate of air leak (in mL/min) from randomisation to 72 hours after the study interventions

    Time frame: 72 hours

  3. Time to air leak cessation

    Time from study intervention to complete cessation of air leak and successful removal of all chest drain(s) (in hours)

    Time frame: 3 months

  4. Length of acute hospital stay

    Length of hospital stay after study intervention (in days)

    Time frame: 3 months

  5. Need for additional (unplanned or elective) intervention for persistent air leak

    The need for additional (unplanned or elective) interventions for persistent air leak, which includes needle aspiration, chest drain insertion, implantation of endobronchial valve, surgery

    Time frame: 3 months

  6. Recurrence of ipsilateral pneumothorax

    Recurrence of ipsilateral pneumothorax after study intervention

    Time frame: 3 months

  7. Changes in inflammatory markers

    Changes in inflammatory markers, including white blood cells and C-reactive protein

    Time frame: 3 months

  8. Breathlessness score

    Breathlessness by visual analogue scale, score ranges from 0 to 100, with 0 means no breathlessness, and 100 means the worst breathlessness ever

    Time frame: 3 months

  9. Pain score

    Pain score in visual analogue scale, score ranges from 0 to 10, with 0 means no pain, and 10 means the worst pain ever

    Time frame: 3 months

  10. Occurrence of complications

    Occurrence of complications, including chest drain blockage, dislodgement, fever, pleural infection / empyema, acute respiratory distress syndrome (ARDS)

    Time frame: 3 months

  11. Protocol adherence

    The reason and frequency of protocol violation throughout the study period

    Time frame: 3 months

  12. Adverse events

    Incidence, severity, and timing of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Nov 2029, 35 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Nov 2026 → Dec 2026, primary completion Oct 2029 → Nov 2029 and completion Mar 2030 → Apr 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2025
First posted
Mar 19, 2025
StartEst.
Dec 1, 2026was Nov 2026
Primary completionEst.
Nov 30, 2029was Oct 2029
CompletionEst.
Apr 30, 2030was Mar 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 1, 2026→Dec 1, 2026
Oct 26, 2026
Primary completion
Oct 31, 2029→Nov 30, 2029
Oct 26, 2026
Study completion
Mar 31, 2030→Apr 30, 2030
Oct 26, 2026
Eligibility
1 inclusion criterion edited, 1 added, 1 removed; 5 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedSSP with air leak persists for ≥3at least 2 days after the first radiographic evidence of pneumothorax
  • RemovedIntend to administer talc or autologous blood patch therapy (ABPT) to stop the air leak as the next step of treatment
  • AddedNot suitable, as decided by the attending medical or surgical team, or the patient is unwilling to receive surgical management for the pneumothorax
Exclusion criteria
  • EditedImpaired blood clotting, including baseline INR > 1.5, platelet < 150 x 10\^9109/L, or use of therapeutic dose anticoagulant or dual-antiplatelet agents.
  • EditedActive or recent (within 6 weeks) ipsilateral pleural infection.
  • EditedSepticaemiaSepticemia or active extrapleuralextra-pleural infection (e.g. pneumonia).
  • EditedExpected survival of less than three months from a different pathology to thisthe current episode of pneumothorax (e.g. metastatic malignancy).
  • EditedCognitively impaired and physically unable to follow the turning procedure during intrapleural procedure, orpatients who are at risk of self-removing the chest drain
Oct 26, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionFeasibility of pilot study trial protocol including the following criteria: how it is measured was reworded
Oct 26, 2026
Secondary outcomes
3 edited, 3 time frame changed, 1 removed, 2 description edited
What changed in the outcomes
  • EditedLength of acute hospital stayTime frame: 3 months
  • EditedNeed for additional (unplanned or elective) additional intervention for persistent air leakTime frame: 3 months
  • EditedRecurrence of ipsilateral pneumothoraxTime frame: 3 months
  • RemovedTime to interventionTime frame: 72 hours
  • Time frameComplete cessation of air leak3 days → 72 hours
  • Time frameChange in air leak3 days → 72 hours
  • Time frameTime to air leak cessation30 days → 3 months
  • DescriptionChange in air leak: how it is measured was reworded
  • DescriptionProtocol adherence: how it is measured was reworded
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Nov 1, 2026→Dec 1, 2026
    Primary completion Oct 31, 2029→Nov 30, 2029
    Study completion Mar 31, 2030→Apr 30, 2030
    Eligibility 1 inclusion criterion edited, 1 added, 1 removed; 5 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedSSP with air leak persists for ≥3at least 2 days after the first radiographic evidence of pneumothorax
    • RemovedIntend to administer talc or autologous blood patch therapy (ABPT) to stop the air leak as the next step of treatment
    • AddedNot suitable, as decided by the attending medical or surgical team, or the patient is unwilling to receive surgical management for the pneumothorax
    Exclusion criteria
    • EditedImpaired blood clotting, including baseline INR > 1.5, platelet < 150 x 10\^9109/L, or use of therapeutic dose anticoagulant or dual-antiplatelet agents.
    • EditedActive or recent (within 6 weeks) ipsilateral pleural infection.
    • EditedSepticaemiaSepticemia or active extrapleuralextra-pleural infection (e.g. pneumonia).
    • EditedExpected survival of less than three months from a different pathology to thisthe current episode of pneumothorax (e.g. metastatic malignancy).
    • EditedCognitively impaired and physically unable to follow the turning procedure during intrapleural procedure, orpatients who are at risk of self-removing the chest drain
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionFeasibility of pilot study trial protocol including the following criteria: how it is measured was reworded
    Secondary outcomes 3 edited, 3 time frame changed, 1 removed, 2 description edited
    What changed in the outcomes
    • EditedLength of acute hospital stayTime frame: 3 months
    • EditedNeed for additional (unplanned or elective) additional intervention for persistent air leakTime frame: 3 months
    • EditedRecurrence of ipsilateral pneumothoraxTime frame: 3 months
    • RemovedTime to interventionTime frame: 72 hours
    • Time frameComplete cessation of air leak3 days → 72 hours
    • Time frameChange in air leak3 days → 72 hours
    • Time frameTime to air leak cessation30 days → 3 months
    • DescriptionChange in air leak: how it is measured was reworded
    • DescriptionProtocol adherence: how it is measured was reworded
    + 6 other changes: identifiers, verification date, responsible party, oversight details, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06883188
Collaborators
Queen Elizabeth Hospital, Hong Kong, Princess Margaret Hospital, Hong Kong, Pamela Youde Nethersole Eastern Hospital
Responsible party
Ka Pang Chan (Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Mar 19, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 30, 2029 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Ka Pang Chan, MBChB
Contact
chankapang@cuhk.edu.hk
+852 3505 2211
David SC Hui, MD
study director · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion